Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.64)
# 911
Out of 5,008 analysts
173
Total ratings
48.52%
Success rate
7.06%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Upgrades: Market Outperform | $33 | $20.44 | +61.45% | 12 | Oct 6, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $13.78 | +45.14% | 13 | Sep 24, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $2.43 | +146.91% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $23.41 | +45.24% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $26.92 | +67.16% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $39.63 | +26.17% | 23 | Jul 29, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $70.62 | +21.78% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $3.66 | +63.93% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $5.52 | +171.74% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $4.72 | +27.12% | 13 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $5.87 | +2.21% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.42 | +103.62% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $33.80 | +255.03% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $7.01 | +156.78% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $7.99 | +150.31% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.91 | +790.05% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $6.23 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.13 | +253.98% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $5.83 | +260.21% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.72 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.82 | +57.07% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $178.96 | +56.46% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.65 | +86.53% | 1 | Jan 26, 2023 |
Intellia Therapeutics
Oct 6, 2025
Upgrades: Market Outperform
Price Target: $33
Current: $20.44
Upside: +61.45%
Benitec Biopharma
Sep 24, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $13.78
Upside: +45.14%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $2.43
Upside: +146.91%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $23.41
Upside: +45.24%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $26.92
Upside: +67.16%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $39.63
Upside: +26.17%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $70.62
Upside: +21.78%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.66
Upside: +63.93%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.52
Upside: +171.74%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $4.72
Upside: +27.12%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $5.87
Upside: +2.21%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.42
Upside: +103.62%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $33.80
Upside: +255.03%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.01
Upside: +156.78%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $7.99
Upside: +150.31%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.91
Upside: +790.05%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.23
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.13
Upside: +253.98%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $5.83
Upside: +260.21%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.72
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.82
Upside: +57.07%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $178.96
Upside: +56.46%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.65
Upside: +86.53%